Global Terbinafine (Lamisil) Market Size By Type (Oral, External Use), By Application (Fungal Infection Of The Skin And Mucous Membrane, Onychomycosis), By Region, And Segment Forecasts, 2023 to 2032

The Global Terbinafine (Lamisil) Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.1 billion by 2031, growing at a CAGR of 6.0% during the forecast period. Terbinafine, marketed under brand names such as Lamisil, is an antifungal agent widely used for treating onychomycosis (fungal nail infections) and dermatophytoses. Market growth is driven by the rising prevalence of fungal infections, increasing awareness of personal hygiene, and growing demand for over-the-counter (OTC) antifungal medications.

Drivers

1. Increasing Prevalence of Fungal Infections

Global warming and changing climatic conditions have led to higher incidences of fungal infections. Additionally, increased prevalence among diabetic and immunocompromised individuals is driving demand for terbinafine.

2. Growing Preference for OTC Antifungal Treatments

The accessibility of terbinafine as a topical and oral medication without a prescription in several countries has expanded its consumer base and market potential.

3. Advancements in Drug Delivery Technologies

Improved formulations such as sprays, gels, and sustained-release tablets are enhancing patient compliance and expanding the market.

Restraints

1. Potential Side Effects and Contraindications

Long-term oral use of terbinafine can lead to liver toxicity and gastrointestinal disturbances, which can limit its adoption in certain populations.

2. Generic Competition

Patent expiration and the proliferation of generic terbinafine products are leading to price erosion, impacting revenue for branded formulations like Lamisil.

Opportunity

1. Market Penetration in Developing Regions

Rising awareness, improved access to healthcare, and increasing healthcare expenditure in regions such as Asia-Pacific and Latin America present lucrative growth opportunities.

2. Expansion of E-Commerce and Digital Pharmacies

The shift toward online platforms for healthcare products is driving sales of antifungal medications, particularly in urban areas with higher internet penetration.

Market by System Type Insights

By formulation, the Oral Terbinafine segment dominated the market in 2023. Oral terbinafine is widely prescribed due to its systemic efficacy in treating nail and skin fungal infections. However, the Topical Terbinafine segment is projected to witness significant growth due to fewer side effects, better safety profiles, and increased demand in pediatric and elderly populations.

Market by End-use Insights

In terms of end-use, Retail Pharmacies accounted for the largest market share in 2023 due to their widespread accessibility and consumer trust. Meanwhile, Online Pharmacies are expected to grow at the fastest pace, supported by the global shift toward digital healthcare services and direct-to-consumer models.

Market by Regional Insights

North America led the global terbinafine market in 2023, driven by high awareness levels, established pharmaceutical infrastructure, and a significant patient population suffering from fungal infections. Asia-Pacific, however, is poised to experience the fastest growth during the forecast period, propelled by rising healthcare investments, increasing disposable income, and unmet clinical needs in rural regions.

Competitive Scenario

Key players operating in the global terbinafine market include:

Novartis AG (original brand Lamisil)

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Sun Pharmaceutical Industries Ltd.

Glenmark Pharmaceuticals

Hikma Pharmaceuticals

Apotex Inc.

Almirall, S.A.

Companies are focusing on expanding product availability, launching combination antifungal therapies, and enhancing online pharmacy distribution. For example:

In 2023, Glenmark launched a new topical terbinafine spray targeting patients seeking faster relief from athlete’s foot.

In 2024, Novartis extended its Lamisil OTC product line into emerging markets, including Southeast Asia and Eastern Europe.

Scope of Work – Global Terbinafine (Lamisil) Market

Key Market Developments

2023: Teva Pharmaceuticals expanded its distribution channels through Amazon Pharmacy for generic terbinafine tablets.

2024: Sun Pharma announced a strategic alliance to distribute terbinafine formulations across sub-Saharan Africa.

2025: Novartis initiated clinical trials for a novel once-weekly oral terbinafine formulation to enhance compliance.

FAQs

1) What is the current market size of the Global Terbinafine (Lamisil) Market?

The market size was USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Terbinafine (Lamisil) Market?

The key growth driver is the rising prevalence of fungal infections globally.

3) Which is the largest region during the forecast period in the Global Terbinafine (Lamisil) Market?

North America is the largest region based on 2023 market share.

4) Which segment accounted for the largest market share in the Global Terbinafine (Lamisil) Market?

The Oral Terbinafine segment held the largest share in 2023.

5) Who are the key market players in the Global Terbinafine (Lamisil) Market?

Major players include Novartis AG, Teva Pharmaceuticals, Glenmark, and Sun Pharma.